| 1 | Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials | Cancer Treatment Reviews | 1997 | 769 |
| 2 | Antitumor Benzothiazoles. 26.12-(3,4-Dimethoxyphenyl)-5-fluorobenzothiazole (GW 610, NSC 721648), a Simple Fluorinated 2-Arylbenzothiazole, Shows Potent and Selective Inhibitory Activity against Lung, Colon, and Breast Cancer Cell Lines | Journal of Medicinal Chemistry | 2006 | 458 |
| 3 | Increased protein degradation and decreased protein synthesis in skeletal muscle during cancer cachexia | British Journal of Cancer | 1993 | 120 |
| 4 | Antitumour imidazotetrazines—XV | Biochemical Pharmacology | 1987 | 104 |
| 5 | Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide | Cancer Chemotherapy and Pharmacology | 1991 | 86 |
| 6 | Structural Studies on Bioactive Compounds. 40.1Synthesis and Biological Properties of Fluoro-, Methoxyl-, and Amino-Substituted 3-Phenyl-4H-1-benzopyran-4-ones and a Comparison of Their Antitumor Activities with the Activities of Related 2-Phenylbenzothiazoles | Journal of Medicinal Chemistry | 2006 | 77 |
| 7 | Antitumor Polycyclic Acridines. 20.(1) Search for DNA Quadruplex Binding Selectivity in a Series of 8,13-Dimethylquino[4,3,2-kl]acridinium Salts: Telomere- Targeted Agents | Journal of Medicinal Chemistry | 2008 | 75 |
| 8 | The role of protein kinase C isoenzymes in the growth inhibition caused by bryostatin 1 in human A549 lung and MCF-7 breast carcinoma cells | International Journal of Cancer | 1994 | 65 |
| 9 | Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity | Cancer Chemotherapy and Pharmacology | 1990 | 61 |
| 10 | Quinols as Novel Therapeutic Agents. 2.14-(1-Arylsulfonylindol-2-yl)-4-hydroxycyclohexa-2,5-dien-1-ones and Related Agents as Potent and Selective Antitumor Agents | Journal of Medicinal Chemistry | 2005 | 56 |
| 11 | Alteration of serum and urinary lipolytic activity with weight loss in cachectic cancer patients | British Journal of Cancer | 1990 | 54 |
| 12 | Effects of activators of protein kinase C, including bryostatins 1 and 2, on the growth of A549 human lung carcinoma cells | International Journal of Cancer | 1989 | 53 |
| 13 | Novel Thioredoxin Inhibitors Paradoxically Increase Hypoxia-Inducible Factor-α Expression but Decrease Functional Transcriptional Activity, DNA Binding, and Degradation | Clinical Cancer Research | 2006 | 47 |
| 14 | Studies of the metabolism of dimethylformamide in mice | Chemico-Biological Interactions | 1983 | 43 |
| 15 | Antiproliferative properties of phorbol ester tumour promoters | Biochemical Pharmacology | 1985 | 43 |
| 16 | Identification by proton NMR of N-(hydroxymethyl)-N-methylformamide as the major urinary metabolite of N, N-dimethylformamide in mice | Life Sciences | 1986 | 43 |
| 17 | Metabolic substrate utilization by tumour and host tissues in cancer cachexia | Biochemical Journal | 1991 | 37 |
| 18 | An investigation of the mechanism of hepatotoxicity of the antitumour agent N-methylformamide in mice | Biochemical Pharmacology | 1984 | 34 |
| 19 | The effects of nitrogen mustard (HN2) on activities of the plasma membrane of PC6A mouse plasmacytoma cells | Biochemical Pharmacology | 1982 | 32 |
| 20 | The role of isocyanates in the toxicity of antitumour haloalkylnitrosoureas | Biochemical Pharmacology | 1982 | 28 |
| 21 | Antitumour imidazotetrazines—XVI | Biochemical Pharmacology | 1987 | 28 |
| 22 | The metabolism of triazene antitumor drugs | | 1987 | 26 |
| 23 | The formation and metabolism of N-hydroxymethyl compounds-IV | Biochemical Pharmacology | 1983 | 22 |
| 24 | Modulation by staurosporine of phorbol-ester-induced effects on growth and protein kinase C localization in a549 human lung-carcinoma cells | International Journal of Cancer | 1992 | 22 |
| 25 | Alterations in serum lipolytic activity of cancer patients with response to therapy | British Journal of Cancer | 1990 | 21 |
| 26 | Biochemistry of topoisomerase I and II inhibition by anthracenyl-amino acid conjugates | Biochemical Pharmacology | 1995 | 20 |
| 27 | Synthetic studies of 8-carbamoylimidazo-[5,1-d]-1,2,3,5-tetrazin-4(3H)-one: A key derivative of antitumour drug temozolomide | Bioorganic and Medicinal Chemistry Letters | 1996 | 19 |
| 28 | Induction of haemoglobin synthesis in the human leukaemia cell line K562 by monomethyltriazenes and imidazotetrazinones | Biochemical Pharmacology | 1985 | 18 |
| 29 | The chemosensitivity of a new experimental model—the M5076 reticulum cell sarcoma | European Journal of Cancer & Clinical Oncology | 1984 | 17 |
| 30 | EORTC/CRC/NCI guidelines for the formulation of investigational cytotoxic drugs | European Journal of Cancer & Clinical Oncology | 1988 | 17 |
| 31 | Medicinal Azides. Part 3. The Metabolism of the Investigational Antitumour Agent Meta-Azidopyrimethamine in Mouse Tissuein vitro | Xenobiotica | 1988 | 17 |
| 32 | A new light on the photo-decomposition of the antitumour drug DTIC | Journal of Pharmacy and Pharmacology | 2011 | 17 |
| 33 | Studies on the toxicity of the antitumour agent N-methylformamide in mice☆ | Toxicology | 1985 | 16 |
| 34 | Cytoskeletal proteolysis during calcium-induced morphological transitions of human erythrocytes | Experimental Cell Research | 1992 | 16 |
| 35 | Role of the extracellular matrix on the growth and differentiated phenotype of murine colonic adenocarcinoma cellsin vitro | International Journal of Cancer | 1991 | 15 |
| 36 | Studies of the mode of action of antitumour triazenes and triazines—III. Metabolism studies on hexamethylmelamine | Biochemical Pharmacology | 1982 | 14 |
| 37 | Studies of the mode of action of antitumour triazenes and triazines—IV. The metabolism of 1-(4-acetylphenyl)-3,3-dimethyltriazene | Biochemical Pharmacology | 1982 | 14 |
| 38 | Studies of the mode of action of antitumour triazenes and triazines—V. The correlation of the in vitro cytotoxicity and in vivo antitumour activity of hexamethylmelamine analogues with their metabolism | Biochemical Pharmacology | 1984 | 12 |
| 39 | The antitumour effect and toxicity of cis-platinum and N-methylformamide in combination | Cancer Chemotherapy and Pharmacology | 1986 | 12 |
| 40 | Selective inhibition by bis(2-chloroethyl)methylamine (nitrogen mustard) of the Na+/K+/Cl− cotransporter of murine L1210 leukemia cells | Biochimica Et Biophysica Acta - Biomembranes | 1988 | 12 |
| 41 | Labelled compounds of interest as antitumour agents I: N-methylformamide and N, N-dimethylformamide | Journal of Labelled Compounds and Radiopharmaceuticals | 1983 | 11 |
| 42 | Investigations of the action of the antitumor drug adriamycin on tumour cell membrane functions—I | Biochemical Pharmacology | 1985 | 11 |
| 43 | Interaction of the antibiotic adriamycin with the plasma membrane | Advances in Enzyme Regulation | 1985 | 10 |
| 44 | A phase I study of meta-azidopyrimethamine ethanesulphonate (MZPES) ? a new dihydrofolate reductase inhibitor | Cancer Chemotherapy and Pharmacology | 1989 | 10 |
| 45 | Stability-indicating high-performance liquid chromatography assay for the anticancer drug bryostatin 1 | Journal of Chromatography A | 1989 | 9 |
| 46 | Is metabolism an important arbiter of anticancer activity of ether lipids? metabolism of SRI 62-834 and hexadecylphosphocholine by [31P]-NMR spectroscopy and comparison of their cytotoxicities with those of their metabolites | Cancer Chemotherapy and Pharmacology | 1992 | 9 |
| 47 | The effects of adriamycin on intracellular calcium concentrations of L1210 murine leukemia cell | European Journal of Cancer & Clinical Oncology | 1987 | 8 |
| 48 | Antimetastatic drugs: laboratory to clinic | Clinical and Experimental Metastasis | 1984 | 7 |
| 49 | Antitumour imidazotetrazines—VIII | Biochemical Pharmacology | 1985 | 7 |
| 50 | Characterisation of a Na+/K+/Cl− cotransporter in alkylating agent-sensitive L1210 murine leukemia cells | Biochimica Et Biophysica Acta - Biomembranes | 1988 | 7 |
